Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive Tumor|Breast Cancer
Interventions: DRUG: eribulin mesylate|DRUG: capecitabine
Sponsor: Eisai Inc.